External broker reports(aggregated public sources), Axis Direct

Axis Direct

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only.  Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External broker reports(aggregated public sources)

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

<ul><li>Despite flat overall results, biosimilars reported an 11% revenue growth YoY, and there was an improvement in gross margins by 100 basis points YoY, indicating strong business performance.</li><li>Additionally, the launch of Liraglutide and Micafungin in the generics segment is expected to add value.</li><li>Continuous improvement in market share and launches in new geographies will further enhance sales of biosimilars. </li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

Despite flat overall results, biosimilars reported an 11% revenue growth YoY, and there was an improvement in gross margins by 100 basis points YoY, indicating strong business performance.Additionally, the launch of Liraglutide and Micafungin in the generics segment is expected to add value.Continuous improvement in market share and launches in new geographies will further enhance sales of biosimilars. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Biocon Ltd - Weak Operational Performance